<DOC>
	<DOCNO>NCT02108548</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability single multiple ascend oral dos ASP7657 healthy subject .</brief_summary>
	<brief_title>A Study Assess Safety Tolerability , Including Gastrointestinal Safety , Pharmacokinetics Pharmacodynamics ASP7657 Caucasian Healthy Male Female Subjects</brief_title>
	<detailed_description>Subjects healthy male age 18 55 year age ( inclusive ) ( Parts 1 2 , young cohort ) subject elderly healthy male female subject age 65 year ( Part 2 , elderly cohort ) .</detailed_description>
	<mesh_term>Naproxen</mesh_term>
	<criteria>Subject body mass index ( BMI ) range 18.5 30.0 kg/m2 , inclusive . The subject weigh least 50 kg [ screen ] Subject agree undergo gastroduodenoscopy ( GDS ) need ( Part 1 : case gastrointestinal ( GI ) complaints/positive fecal blood test ; Part 2 : subject ) Subject know suspected hypersensitivity ASP7657 naproxen , component formulation use Subject liver function test upper limit normal ( ULN ) Subject clinically significant history allergic condition ( include drug allergy , asthma , eczema , anaphylactic reaction , exclude untreated , asymptomatic , seasonal allergy time dose ) Subject history evidence clinically significant cardiovascular , GI , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal , and/or major disease malignancy Subject has/had febrile illness symptomatic , viral , bacterial ( include upper respiratory infection ) , fungal ( noncutaneous ) infection within 1 week prior day admission Subject clinically significant abnormality Subject pulse &lt; 40 &gt; 90 beat per minute ( bpm ) ; mean systolic blood pressure ( SBP ) &gt; 140 mmHg ; mean diastolic blood pressure ( DBP ) &gt; 90 mmHg ( measurement take triplicate subject rest supine position 5 minute ; pulse measure automatically ) day 1 . ( For elderly subject follow criterion apply : DBP &gt; 100 mmHg , SBP &gt; 160 mmHg [ day admission ] ) Subject mean QT interval correct heart rate use Fridericia 's formula ( QTc ( F ) ) &gt; 430 m ( male ) &gt; 450 m ( female ) . Subject use prescribe nonprescribed drug ( include nonsteroidal antiinflammatory drug ( NSAIDs ) , anticoagulant , vitamin , natural herbal remedy , e.g. , St. John 's wort ) 2 week prior first study drug administration , except occasional use paracetamol ( 2 g/day ) Subject history smoking 10 cigarette ( equivalent amount tobacco ) per day within 3 month prior admission clinical unit . Subject history drinking &gt; 21 unit ( male ) &gt; 14 unit ( female ) alcohol per week ( 1 unit = 10 g pure alcohol = 250 mL beer [ 5 % ] 35 mL spirit [ 35 % ] 100 mL wine [ 12 % ] ) within 3 month prior admission clinical unit subject test positive screen clinical admission alcohol drug abuse ( amphetamine , barbiturate , benzodiazepine , cannabinoids , cocaine , opiates ) Subject use drug abuse within 3 month prior admission clinical unit Subject significant blood loss , donate 1 unit ( 450 mL ) blood , receive transfusion blood blood product within 60 day donate plasma within 7 day prior clinic admission Subject use inducer metabolism ( e.g. , barbiturate , rifampin ) 3 month prior admission clinical unit regularly Subject positive serology test hepatitis B surface antigen ( HBsAg ) , antihepatitis A virus ( HAV ) ( immunoglobulin [ Ig ] M ) , antihepatitis C virus ( HCV ) antihuman immunodeficiency virus ( HIV ) 1+2 Subject positive H.Pylori test screening Subject positive fecal blood test screen Subject participate interventional clinical study treat investigational drug within 90 day 5 halflives whichever longer , prior initiation screen Subject employee Astellas Group Clinical Research Organization involve study Subject history peptic ulceration significant dyspepsia Subject use concomitant medication associate peptic ulceration , presence risk factor peptic ulceration Subject , nonelderly , endoscopic evidence inflammation , ulceration , erosion , mucosal hemorrhage , active bleeding esophagus , stomach , pyloric channel duodenum , mucosal grade scale score &gt; 2 stomach duodenum baseline visit ( Part 2 healthy young male cohort )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>ASP7657</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Healthy Subjects</keyword>
	<keyword>First man</keyword>
	<keyword>Safety</keyword>
</DOC>